Amarin Corporation PLC (AMRN) Upgraded to “Hold” at ValuEngine

Amarin Corporation PLC (NASDAQ:AMRN) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Saturday, November 4th.

AMRN has been the topic of a number of other research reports. Zacks Investment Research lowered Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Amarin Corporation PLC in a research note on Wednesday, October 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. BidaskClub lowered Amarin Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.75.

Shares of Amarin Corporation PLC (NASDAQ AMRN) traded up $0.04 during mid-day trading on Friday, hitting $3.36. The stock had a trading volume of 842,300 shares, compared to its average volume of 1,739,161. Amarin Corporation PLC has a twelve month low of $2.81 and a twelve month high of $4.47. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $45.85 million. During the same quarter in the prior year, the business earned ($0.08) EPS. The company’s quarterly revenue was up 45.4% compared to the same quarter last year. sell-side analysts anticipate that Amarin Corporation PLC will post -0.22 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/markets/amarin-corporation-plc-amrn-lifted-to-hold-at-valuengine/1758423.html.

In other news, insider Steven B. Ketchum sold 63,479 shares of Amarin Corporation PLC stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 3.72% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Westside Investment Management Inc. raised its holdings in shares of Amarin Corporation PLC by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 300 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Amarin Corporation PLC by 4.8% during the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. State Street Corp raised its holdings in shares of Amarin Corporation PLC by 1.3% during the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after buying an additional 2,640 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Amarin Corporation PLC by 0.9% during the 1st quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after buying an additional 3,413 shares during the period. Finally, Perkins Capital Management Inc. increased its holdings in Amarin Corporation PLC by 20.3% during the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors and hedge funds own 39.08% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.